The year is off to a positive start in terms of publications. Two new papers related to Burua Scientific have appeared. One of them even incorporates Burua Scientific in the authors’ addresses: the first official Burua publication!
In fact, both come from previous collaborations of our founder. He has been working in the industry for years, but fortunately has had the opportunity to continue collaborating and publishing. Collaborations, for him and for Burua, are fundamental. They are a way of transferring knowledge to society, of giving it back to the community. At the same time they allow to give visibilty to what we do; they help us to try to be at the forefront and at the same time to be judged for it. They allow us to have a more or less objective idea of the quality/validity of what we do for the scientific community. Therefore, they are basic for us.
We also have to bear in mind that we are not just a service provider. That we are, that’s true, but we also want to establish collaborations with companies and researchers in public and non-profit organisations to make disruptive discoveries. We believe that collaboration will allow us to have a greater impact on society.
The first paper, published in January, was Laura’s latest PhD work. It was the result of a fruitful public-private collaboration between the Universitat de Barcelona and the former Mind the Byte, which has yielded several interesting scientific results related to the potential of marine molecules, especially meridianins, as possible therapeutic agents in neurodegenerative diseases, in particular Alzheimer’s.
This particular work is a further confirmation of the potential of CADD techniques in marine drug discovery, specifically the deorphanisation of marine molecules. Interestingly, due to the high access rate, the article is now displayed on the Marine Drugs home page!
The second paper, published in February, is an article published by the Translink consortium. Translink was a large multidisciplinary EU-funded project with the aim to “Define the role of xeno-targeting and autoimmune events in patients receiving animal-derived bioprosthetic heart valves”.
Bioprosthetic heart valves in humans calcify due to antibody immune responses to sugar antigens (Neu5Gc and alpha-Gal xenoglycans). However, the translink project has shown that the use of tissues from knock-out animals that do not express these glycans may be a solution to the problem, which is good news for the future.
All in all, a good start to the publishing year! Let’s hope for more successful publications and collaborations to come.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.